SAB Biotherapeutics, Inc.SABSNASDAQ
Loading
PB Ratio: Premium ValuationElevated
Percentile Rank17
3Y CAGR-16.8%
5Y CAGR-46.9%
Year-over-Year Change
Price-to-book ratio
3Y CAGR
-16.8%/yr
Annual compound
5Y CAGR
-46.9%/yr
Recent acceleration
Percentile
P17
Within normal range
vs 5Y Ago
0x
Contraction
Streak
1 yr
Consecutive declineElevated
| Period | Value | YoY Change |
|---|---|---|
| 2025 | 0.48 | -64.7% |
| 2024 | 1.35 | +103.9% |
| 2023 | 0.66 | -19.8% |
| 2022 | 0.83 | -90.6% |
| 2021 | 8.81 | -22.1% |
| 2020 | 11.31 | +105.9% |
| 2019 | -191.37 | - |